FUTURE Products

Modern science has allowed today's researchers to bring a greater number of drug candidates into development than ever before - all needing crucial ADMET evaluation. Millions in investment dollars and critical research time are lost if a compound fails during development, and development failures are often the result of ADMET challenges.

The team at Qualyst is dedicated to delivering more efficient and effective ADMET screening products to the life sciences sector every year, providing better knowledge for faster and more accurate results.

Qualyst continually seeks out and develops novel technologies within the ADMET area. Our goal is to bring at least one novel ADMET product to the marketplace each year. Qualyst pursues an aggressive in-licensing strategy for technologies amenable to development into medium- and high-throughput screens, or cell-based technologies that add new insight into the ADMET area. To submit a technology for consideration, please email a non-confidential summary and any published patent applications (US or PCT) to IP [AT] qualyst [DOT] com.